Low dose (2 × 2 Gy) involved field radiotherapy in recurrent indolent lymphomas induces rapid and lasting remissions without significant toxicity; results of the HORA-1 phase II study

2001 ◽  
Vol 37 ◽  
pp. S92
Author(s):  
R. Haas ◽  
B. Aleman ◽  
L. Dewit ◽  
D. de Jong ◽  
H. Bartelink
Keyword(s):  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Significant Toxicity ◽  
Indolent Lymphomas ◽  
Involved Field ◽  
Involved Field Radiotherapy

Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy in Advanced Lymphoma: A Phase II Study

2008 ◽  
Vol 8 (4) ◽  
pp. 241-245 ◽  
Author(s):  
Vedang Murthy ◽  
Karen Thomas ◽  
Kerwyn Foo ◽  
David Cunningham ◽  
Bernadette Johnson ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Field Radiation ◽  
Involved Field

scholarly journals A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer

2018 ◽  
Vol 38 (12) ◽  
pp. 6911-6917 ◽  
Author(s):  
SHO SATO ◽  
CHIKARA KUNISAKI ◽  
YUSAKU TANAKA ◽  
KEI SATO ◽  
HIROSHI MIYAMOTO ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study

scholarly journals Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study

2007 ◽  
Vol 177 (6) ◽  
pp. 2136-2140 ◽  
Author(s):  
R. Lord ◽  
S. Nair ◽  
A. Schache ◽  
J. Spicer ◽  
Navita Somaihah ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Study ◽  
Oral Cyclophosphamide ◽  
Hormone Resistant Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document